Ironwood Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 9 of about 9   

Articles published

IRWD 14.95 +0.38 (2.61%)
price chart
Synergy Pharmaceuticals Strengthened By Merger Agreement
With that being said, Synergy may hold a distinct advantage with Plecanatide over Ironwood's Linaclotide that positions the company to achieve quick market share, should it make it to market. During Ironwood's Linaclotide trials, the treatment was ...
Related articles »  
The Best Boring Companies in Biotech
�Ironwood Pharmaceuticals (NASDAQ: IRWD). This company, based in Cambridge, MA, was the bellwether biotech IPO of 2010, coming out of the gate during some dismal times with a market valuation of more than $1 billion.
Battered Sucampo bets big on bowel drug
Sucampo still retains its highest hopes for Amitiza - approved to treat types of constipation and irritable bowel syndrome - despite slow sales growth and potential competition from Ironwood Pharmaceutical Inc.'s Linaclotide. �We still believe based ...
Earnings Preview: Forest Laboratories
On April 23, 2012, Ironwood Pharmaceuticals Inc and Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting ...
28 Drugs Facing FDA Approval in 2012-2013
BOSTON ( TheStreet) -- Here's an updated list of biotech and pharmaceutical companies with pending FDA drug approval decisions for the rest of 2012 and into early 2013.
Biotechs With Upcoming PDUFA Dates
Ironwood Pharmaceuticals (NASDAQ: IRWD) - Ironwood has a PDUFA date on September 9 for a product called Linaclotide.
US FDA backs Forest and Almirall's Tudorza Pressair to treat COPD
US drugmaker Forest Laboratories (NYSE: FRX) and Spain's largest pharmaceutical firm Almirall (ALM: MC), which originated the drug, said yesterday that the US Food and Drug Administration has approved their Tudorza Pressair (aclidinium bromide ...
Related articles »  
Ferring Acquires Rights to Albireo's Late-Stage IBS Drug
Ferring licensed near-global rights to Swedish firm Albireo's irritable bowel disease (IBS) drug elobixibat, which is in preparation for both for Phase III trials in patients with chronic idiopathic constipation, and Phase IIb trials against ...
Kavoogian and Kinlin of CBRE/NE represent MassBio in 12157 s/f lease ...
Cambridge, MA CB Richard Ellis - N.E. Partners, LP (CBRE/NE) completed a new lease with Alexandria Real Estate Equities, Inc. at 300 Technology Sq. MassBio, the leading advocate for the Bay State's world premier life science cluster, has relocated from ...